Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Paracetamol 500 mg Clear all
Completed Phase 2 Interventional Results available

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

NCT04165096
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Estrogen Treatment on Drug Metabolism and Transport

NCT05469204
View directory record Official record
Conditions
Transgender Persons
Interventions
Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet, Midazolam Injectable Solution
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Recruiting Phase 2 Interventional

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT07252739
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers

NCT02761980
View directory record Official record
Conditions
Fever
Interventions
Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

NCT01229449
View directory record Official record
Conditions
Post-operative Pain
Interventions
Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
16 Years and older
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

NCT01453400
View directory record Official record
Conditions
Pharyngitis
Interventions
Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo, Acetaminophen + placebo, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

NCT03879408
View directory record Official record
Conditions
Pain
Interventions
440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Results available

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

NCT02432456
View directory record Official record
Conditions
Wounds and Injuries, Rib Fractures
Interventions
Ketamine, Placebo, Intercostal Nerve Block, Acetaminophen, Ibuprofen, Pantoprazole, Methocarbamol, Opioid
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management

NCT02074709
View directory record Official record
Conditions
Postoperative Pain
Interventions
Plain bupivacaine, Liposomal bupivacaine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

NCT03448536
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Naproxen Sodium, (Aleve, BAY117031), Acetaminophen (Tylenol Extra Strength)
Drug
Lead sponsor
Bayer
Industry
Eligibility
15 Years to 35 Years · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Chandler, Arizona • Scottsdale, Arizona • Pinellas Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 28, 2026, 9:28 PM EDT
Terminated Phase 4 Interventional Results available

Post-operative Analgesia in Elective, Soft-tissue Hand Surgery

NCT02029235
View directory record Official record
Conditions
Carpal Tunnel, Ganglion Cyst, Trigger Finger, De Quervain Disease
Interventions
Acetaminophen/Ibuprofen, Acetaminophen/Hydrocodone
Drug
Lead sponsor
Alexander Payatakes, M.D.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain

NCT03224403
View directory record Official record
Conditions
Post-operative Dental Pain
Interventions
Test acetaminophen, Commercial acetaminophen, Commercial ibuprofen, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 28, 2026, 9:28 PM EDT
Withdrawn Phase 4 Interventional

Randomized Trial of Two Analgesics in Elderly ED Patients

NCT02703610
View directory record Official record
Conditions
Pain
Interventions
Oxycodone/acetaminophen, Ibuprofen/acetaminophen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 28, 2026, 9:28 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Onset of Action of a Fast Release Aspirin

NCT01420094
View directory record Official record
Conditions
Healthy Subjects
Interventions
Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 2 Interventional

Study of Acetaminophen (ACE) in Post-operative Dental Pain

NCT02320708
View directory record Official record
Conditions
Dental Pain
Interventions
Acetaminophen (ACE) (1000 mg), Commercial ACE (1000 mg), Commercial Ibuprofen (IBU) (400 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
17 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics

NCT00768716
View directory record Official record
Conditions
Pain, Fever, Hepatotoxicity
Interventions
Acetaminophen
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

NCT02837952
View directory record Official record
Conditions
Pain
Interventions
FDC IBU/APAP 250 mg/500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 28, 2026, 9:28 PM EDT
Completed Phase 1 Interventional

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

NCT02648490
View directory record Official record
Conditions
Solid Tumour
Interventions
HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
Drug
Lead sponsor
Henlix, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 28, 2026, 9:28 PM EDT